Tag Archive for: Johnson & Johnson

The agency stated that companies will be required to add a serious warning on the prescribing information for cancer therapies known as CAR-T, made by Gilead Sciences, Johnson & Johnson, Novartis and others.

Johnson & Johnson’s small molecule FGFR kinase inhibitor is now indicated for patients with susceptible FGFR3 mutations who progressed after at least one line of systemic therapy.

The pharma companies may be served with subpoenas to appear before the Senate health committee to explain why their products are much more expensive in the U.S. than in other countries, according to chairman Sen. Bernie Sanders.

Following the J.P. Morgan Healthcare Conference and other parallel meetings in San Francisco, it’s time to reflect on some of the significant deals secured last week.

Ambrx is developing therapies that belong to the class of drugs called antibody drug conjugates (ADC), which are described by researchers as “guided missiles” to target cancer cells and minimize damage to healthy tissue.

The ruling on Monday by U.S. District Judge Denise Cote in Manhattan federal court likely means the end of a consolidated mass tort litigation of about 500 lawsuits over the popular over-the-counter drug, unless plaintiffs get it reversed on appeal.

Several big-name drugmakers are weighing in on the opportunity in the weight-loss drugs market.

J&J faces more than 50,000 lawsuits over talc, most by women with ovarian cancer, with a minority of the cases involving people with mesothelioma.

The company forecasted revenue growth of 5-6% for the next year, as it banks on strong demand for cancer treatments Darzalex and Carvykti and resilient sales of blockbuster drug Stelara.

In recent years, J&J has pumped hundreds of millions of dollars into its artificial intelligence (AI) capabilities, according to the WSJ, including bringing on some 6,000 data science and digital specialists and erecting a “cutting-edge” research facility in the San Francisco Bay Area, which it opened in September 2022.